‘Tranq’: perceptions of xylazine and harm reduction practices among people receiving treatment for substance use disorders

Xylazine is increasingly present in the drug supply, yet susceptibility to exposure does not appear to influence engagement in harm reduction behaviors. Limited use and knowledge of test strips, as well as other overdose prevention behaviors, highlights the need for targeted harm reduction education. Healthcare providers in all practice settings should be aware of the potential risks posed by xylazine exposure and prioritize evidence-based care, including harm reduction.